• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Morris on the significance of the emergence of 177Lu-PSMA-617 in prostate cancer


Michael J. Morris, MD, discusses the rise of radiopharmaceuticals in prostate cancer and, in particular, the success of 177Lu-PSMA-617 (LuPSMA). Data from the phase 3 VISION trial presented at the 2021 ASCO Annual Meeting showed that adding Lu-PSMA-617 to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. Morris, a medical oncologist and section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, was the lead study author on the VISION trial (J Clin Oncol 39, 2021 [suppl 15; abstr LBA4]).

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.